Algorithmiq
Overview
Quantum algorithms and error mitigation software for life sciences. Develops Tensor Estimation (TEM) error mitigation and Aurora quantum-classical platform for drug discovery. Partners with IBM and runs on IBM Quantum hardware.
Key Milestones
- 2020: Founded by Dr. Sabrina Maniscalco (University of Helsinki) and Dr. Guillermo Garcia-Perez
- 2023: Published TEM (Tensor Estimation Method) — achieved 100× noise reduction on real hardware
- 2024: Partnered with IBM for drug discovery workflows on IBM Quantum systems
- 2025: Demonstrated quantum simulation of cancer drug molecule on 100+ qubit IBM processor
- 2026: Selected as finalist in Wellcome Leap Q4Bio healthcare quantum competition (with IBM + Cleveland Clinic)
Technology Approach
Algorithmiq focuses on quantum algorithms for drug discovery — specifically, using quantum computers to simulate molecular interactions that classical computers can’t handle. Their key innovation is TEM (Tensor Error Mitigation), which dramatically reduces noise in quantum computations without requiring full error correction.
Rather than building hardware, Algorithmiq builds the software and algorithms that run on existing quantum hardware (primarily IBM Quantum). This positions them to benefit from any hardware improvements without the capital expenditure of building quantum computers.
Healthcare Focus
In 2026, Algorithmiq was selected as a finalist in the Wellcome Leap Q4Bio competition — a $5M prize for demonstrating quantum advantage in healthcare. Their team (with IBM and Cleveland Clinic) is working on cancer drug simulation.
Competitive Position
Strengths: Strong scientific team, hardware-agnostic approach, early focus on the highest-value quantum application (drug discovery).
Challenges: Dependent on third-party hardware improvements. Software-only quantum companies face commoditisation risk as hardware vendors build their own application layers.